Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens

Abstract

Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a "Trojan horse" active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms, and stability against all carbapenemases.